Back to top
more

Molina Healthcare (MOH)

(Delayed Data from NYSE)

$189.30 USD

189.30
1,681,252

-1.41 (-0.74%)

Updated Sep 25, 2025 04:00 PM ET

After-Market: $189.22 -0.08 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 5% (234 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Zacks Equity Research

Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss

by Zacks Equity Research

Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Zacks Equity Research

SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut

by Zacks Equity Research

SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.

Zacks Equity Research

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

by Zacks Equity Research

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Zacks Equity Research

Community Health (CYH) Down 30.3% Since Q2 Earnings Report

by Zacks Equity Research

Community Health (CYH) expects capex to remain within $400-$450 million in 2022.

Zacks Equity Research

Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.

Zacks Equity Research

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

Zacks Equity Research

Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down

by Zacks Equity Research

Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.

Zacks Equity Research

Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View

by Zacks Equity Research

Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.

Zacks Equity Research

Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down

by Zacks Equity Research

Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.

Zacks Equity Research

If You Invested $1000 in Molina 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Are Investors Undervaluing Humana (HUM) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Molina Healthcare (MOH) Q2 Earnings Beat, Hikes '22 EPS View

by Zacks Equity Research

Molina Healthcare's (MOH) second-quarter results gain from membership growth within its Medicaid and Medicare lines of business. A hiked adjusted EPS guidance for 2022 is noteworthy.

Zacks Equity Research

Molina (MOH) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Molina (MOH) delivered earnings and revenue surprises of 4.84% and 6.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights Molina, Greif, Arrow, Sonoco and Occidental

by Zacks Equity Research

Molina, Greif, Arrow, Sonoco and Occidental have been highlighted in this Screen of The Week article.

Zacks Equity Research

Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View

by Zacks Equity Research

Centene (CNC) currently has $3.4 billion remaining in its share buyback program.

Zacks Equity Research

Philips' (PHG) Q2 Earnings Down on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q2 top and bottom-line results reflect the negative impact of supply chain constraints and COVID lockdowns in China.

Vasundhara Sawalka headshot

5 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like MOH, GEF, ARW, SON and OXY that are seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

What to Expect From Molina Healthcare's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.

Zacks Equity Research

Molina (MOH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's How Much a $1000 Investment in Molina Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M

by Zacks Equity Research

Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.

Zacks Equity Research

Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJH